108 related articles for article (PubMed ID: 8484981)
1. Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancer.
van der Gaast A; Hulshof C; Kok TC; van Loon E; Splinter TA
Eur J Cancer; 1993; 29A(6):870-3. PubMed ID: 8484981
[TBL] [Abstract][Full Text] [Related]
2. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
Eskelinen M; Tikanoja S; Brown J
Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
Nicolini A; Ferdeghini M; Colombini C; Carpi A
J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients.
Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Schwartz DC
Tumour Biol; 1991; 12(2):82-90. PubMed ID: 2028182
[TBL] [Abstract][Full Text] [Related]
6. CA 549 as a marker in breast cancer.
Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Dorsa R; Schwartz DC
Int J Biol Markers; 1991; 6(3):139-43. PubMed ID: 1791307
[TBL] [Abstract][Full Text] [Related]
7. [Clinical usefulness of CA M26 and CA M29 in breast carcinoma].
Quaranta M; Micelli G; Coviello M; Donadeo A; Lozupone A; Schittulli F
J Nucl Med Allied Sci; 1990; 34(4 Suppl):35-8. PubMed ID: 2092146
[No Abstract] [Full Text] [Related]
8. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.
Bon GG; Kenemans P; Verstraeten R; van Kamp GJ; Hilgers J
Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):107-14. PubMed ID: 8571992
[TBL] [Abstract][Full Text] [Related]
9. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.
Yedema CA; Kenemans P; Wobbes T; Thomas CM; Bon GG; Mulder C; Voorhorst FJ; Verstraeten AA; van Kamp GJ; Hilgers J
Tumour Biol; 1992; 13(1-2):18-26. PubMed ID: 1589694
[TBL] [Abstract][Full Text] [Related]
10. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411
[TBL] [Abstract][Full Text] [Related]
11. An assessment of the clinical usefulness of two serum markers, CA15 3 and HMFG 2 in localized and metastatic breast cancer.
Bliss P; Fisken J; Roulsten J; Leonard RC
Dis Markers; 1993 Jun; 11(1):45-8. PubMed ID: 8358965
[TBL] [Abstract][Full Text] [Related]
12. Carbohydrate antigen 549 in metastatic breast cancer during cytostatic treatment and follow-up.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P
Eur J Cancer; 1992; 28A(4-5):845-50. PubMed ID: 1524905
[TBL] [Abstract][Full Text] [Related]
13. [Determination of MCA, CA 15.3, CA M26, in carcinoma of the breast].
Bumma C; Bramardi AM; Lauria G; Arese P; Marchetti G
J Nucl Med Allied Sci; 1990; 34(4 Suppl):29-32. PubMed ID: 2092137
[No Abstract] [Full Text] [Related]
14. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
Steger GG; Mader R; Derfler K; Moser K; Dittrich C
Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251
[TBL] [Abstract][Full Text] [Related]
15. Serum markers for breast cancer.
Stenman UH; Heikkinen R
Scand J Clin Lab Invest Suppl; 1991; 206():52-9. PubMed ID: 1947760
[TBL] [Abstract][Full Text] [Related]
16. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
17. Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer.
Yenisey C; Güner G
Biochem Soc Trans; 1996 May; 24(2):302S. PubMed ID: 8736960
[No Abstract] [Full Text] [Related]
18. Serum marker combinations in human breast cancer (review).
Lamerz R; Stieber P; Fateh-Moghadam A
In Vivo; 1993; 7(6B):607-13. PubMed ID: 8193281
[TBL] [Abstract][Full Text] [Related]
19. Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer.
Sjöström J; Alfthan H; Joensuu H; Stenman UH; Lundin J; Blomqvist C
Scand J Clin Lab Invest; 2001; 61(6):431-41. PubMed ID: 11681532
[TBL] [Abstract][Full Text] [Related]
20. Circulating CA 549 and other associated antigens in breast cancer patients.
Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R
Oncology; 1994; 51(1):18-21. PubMed ID: 8265097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]